Suppr超能文献

胃黏膜相关边缘区 B 细胞淋巴瘤放疗后长期疗效:回顾性、多中心、国际结外淋巴瘤研究组研究。

Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study.

机构信息

Division Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne and University of Melbourne, Parkville, Victoria, Australia.

出版信息

Ann Oncol. 2013 May;24(5):1344-51. doi: 10.1093/annonc/mds623. Epub 2013 Jan 4.

Abstract

BACKGROUND

We evaluated the long-term results of radiotherapy for patients with gastric marginal zone lymphoma (GMZL).

PATIENTS AND METHODS

We carried out a retrospective, multi-centre study of patients with low-grade GMZL treated by radiotherapy between 17 July 1981 and 25 March 2004.

RESULTS

There were 102 eligible patients. Fifty-eight patients were previously untreated and 44 had recurrent/residual disease after prior treatment (HP eradication, chemotherapy and surgery in 35, 9 and 8 patients, respectively, and 7 had >1 prior therapy). Radiation fields included the stomach /involved nodes in 61 patients and whole abdomen in 41. The median radiotherapy dose to stomach was 40 Gy (range 26-46 Gy) in a median 22 fractions. With a median follow-up after radiotherapy of 7.9 years (range 0.3-24 years), 10- and 15-year freedom from treatment failure (FFTF) was 88% (95% CI 82%-95%). Risk factors for TF were a large-cell component (P = 0.036) and an exophytic growth pattern (P = 0.042). Radiotherapy field size, radiotherapy dose, and failure of prior therapy were not associated with inferior FFTF. Ten-year overall survival was 70% (95% CI 60%-82%).

CONCLUSIONS

Radiotherapy achieves cure for the majority of patients with low-grade GMZL, including patients who have had prior therapy. Several features may predict a poorer outcome.

摘要

背景

我们评估了胃黏膜相关边缘区淋巴瘤(GMZL)患者放疗的长期疗效。

患者和方法

我们进行了一项回顾性多中心研究,纳入了 1981 年 7 月 17 日至 2004 年 3 月 25 日期间接受放疗的低级别 GMZL 患者。

结果

共有 102 例符合条件的患者。58 例患者为初治患者,44 例患者为先前治疗后复发/残留疾病(分别有 35、9 和 8 例患者接受了幽门螺杆菌根除、化疗和手术治疗,7 例患者接受了 >1 种先前治疗)。61 例患者的照射野包括胃/受累淋巴结,41 例患者的照射野为全腹部。胃的中位放疗剂量为 40 Gy(范围 26-46 Gy),中位分割 22 次。放疗后中位随访 7.9 年(范围 0.3-24 年),10 年和 15 年无治疗失败(FFTF)率分别为 88%(95%CI 82%-95%)。TF 的危险因素包括大细胞成分(P=0.036)和外生性生长模式(P=0.042)。照射野大小、放疗剂量和先前治疗失败与较差的 FFTF 无关。10 年总生存率为 70%(95%CI 60%-82%)。

结论

放疗可治愈大多数低级别 GMZL 患者,包括先前接受过治疗的患者。一些特征可能预示着预后不良。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验